Edwards Lifesciences Corporation (EW) financial statements (2021 and earlier)

Company profile

Business Address ONE EDWARDS WAY
IRVINE, CA 92614
State of Incorp. DE
Fiscal Year End December 31
SIC 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,4031,2951,1641,0311,5171,357934
Cash and cash equivalents1,1831,0249046631,1791,187727
Short-term investments219271260368338170208
Restricted cash and investments17      
Receivables515550(9)(9)544(9)(9)
Inventory, net of allowances, customer advances and progress billings802773735662641611625
Inventory802773735662641611625
Prepaid expense75695766595756
Other current assets208172166164168144130
Other undisclosed current assets7212257759456579618
Total current assets:3,0912,9802,6902,5082,9842,7402,355
Noncurrent Assets
Operating lease, right-of-use asset94908576807371
Property, plant and equipment1,3951,2761,1961,1011,060974931
Long-term investments and receivables802599594588586386413
Long-term investments802599594588586386413
Intangible assets, net (including goodwill)1,5051,5021,5011,5011,5041,5381,560
Goodwill1,1731,1701,1681,1661,1681,1571,174
Intangible assets, net (excluding goodwill)331332334335337381386
Deferred income tax assets231215204158172156164
Other noncurrent assets12013815414510210080
Total noncurrent assets:4,1463,8203,7343,5683,5043,2273,219
TOTAL ASSETS:7,2376,8016,4246,0766,4885,9665,574
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:562822849722647752673
Accounts payable197163153152180136151
Accrued liabilities1101121131221179679
Employee-related liabilities237245199166296262198
Taxes payable19426868531915
Other undisclosed accounts payable and accrued liabilities 261316215 239231
Debt   25262424
Derivative instruments and hedges, liabilities39   6  
Restructuring reserve15   17  
Estimated litigation liability38   20  
Other undisclosed current liabilities2412424 187  
Total current liabilities:894846873747902776697
Noncurrent Liabilities
Long-term debt and lease obligation668666661650653647645
Long-term debt, excluding current maturities595595595595594594594
Operating lease, liability73716656595250
Liabilities, other than long-term debt886864837539548493495
Liability for uncertainty in income taxes214199181176172142140
Estimated litigation liability233      
Other liabilities252484466192203160162
Business combination, contingent consideration, liability186181190170173191193
Total noncurrent liabilities:1,5541,5301,4981,1891,2011,1391,140
Total liabilities:2,4482,3762,3711,9362,1031,9151,837
Stockholders' equity
Stockholders' equity attributable to parent4,5744,2103,8393,9014,1483,8153,500
Common stock636635634219218218217
Treasury stock, value(1,904)(1,904)(1,903)(1,894)(1,279)(1,279)(1,277)
Additional paid in capital1,4381,3821,3241,6761,6231,5701,512
Accumulated other comprehensive loss(161)(158)(146)(152)(156)(156)(138)
Retained earnings4,5654,2563,9304,0523,7423,4613,187
Total stockholders' equity:4,5744,2103,8393,9014,1483,8153,500
Other undisclosed liabilities and equity215214214239237237237
TOTAL LIABILITIES AND EQUITY:7,2376,8016,4246,0766,4885,9665,574

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues1,1921,1419251,1291,1741,0941,087
Cost of revenue
(Cost of Goods and Services Sold)
(296)(281)(238)(265)(286)(292)(304)
Gross profit:895860687864888802783
Operating expenses(539)(511)(837)(508)(555)(510)(507)
Other operating expense, net
(Other Nonrecurring (Income) Expense)
    (41)  
Other undisclosed operating income (loss)(5)9(20)2192(8)
Operating income (loss):351358(170)358311294268
Nonoperating income (expense)286(0)23351
Other nonoperating income (expense) 6(0)2 51
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(23)125(28)32
Income (loss) from continuing operations before income taxes:356364(168)365316302271
Income tax expense (benefit)(47)(39)46(54)(35)(27)(29)
Net income (loss) available to common stockholders, diluted:310325(122)311280275242

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):310325(122)311280275242
Other undisclosed comprehensive income    7  
Comprehensive income (loss):310325(122)311287275242
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3)(12)64(7)(18)3
Comprehensive income (loss), net of tax, attributable to parent:306313(116)315280257245

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: